Table of Contents
<< Previous Issue | Oct 2019 (Vol: 2019, Issue: 10) | Next Issue >> |
- Section: Licensing
-
Pfizer Licenses Akcea’s AKCEA-ANGPTL3-LRx
-
Boehringer Ingelheim Targets KRAS Mutations with Lupin’s LNP3794
-
Takeda Bolsters IBD Pipeline by Partnering with Prometheus Biosciences
-
Ipsen Boosts Rare Disease Portfolio with Blueprint’s BLU-782
- Section: Mergers & Acquisitions
-
Sobi Acquires Dova in US$915 M Deal
-
UCB’s Bets on Complement Diseases with US$2.1 B Ra Pharma Acquisition
-
Alexion Continues to Diversify its Portfolio with Achillion Acquisition
- Section: Research & Development
-
Hansoh Pharmaceutical Signs US$1.5 B AI Drug Discovery Collaboration with Atomwise
-
Merck Signs Another Deal with 4D Pharma to Strengthen its Vaccine Portfolio